<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02666001</url>
  </required_header>
  <id_info>
    <org_study_id>206216</org_study_id>
    <secondary_id>AI438-068</secondary_id>
    <nct_id>NCT02666001</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Drug-drug Interaction of BMS 663068 With Methadone and Also With Buprenorphine/Naloxone</brief_title>
  <official_title>A Phase 1, Open-Label, Drug-Drug Interaction Study Between Methadone and BMS-663068; and Between Buprenorphine/Naloxone and BMS-663068</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ViiV Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to assess the effect of multiple doses of BMS-663068 on the
      exposure of methadone in subjects on a stable dose of methadone, and the exposure of
      buprenorphine and norbuprenorphine in subjects on a stable dose of buprenorphine and
      norbuprenorphine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 12, 2016</start_date>
  <completion_date type="Actual">June 29, 2016</completion_date>
  <primary_completion_date type="Actual">June 29, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax for Methadone (Part 1) and buprenorphine and norbuprenorphine (Part 2)</measure>
    <time_frame>Days 1 to 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(TAU) for Methadone (Part 1) and buprenorphine and norbuprenorphine (Part 2)</measure>
    <time_frame>Days 1 to 10</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse events (AEs), serious AEs (SAEs), and AEs leading to discontinuation.</measure>
    <time_frame>For AEs, Days 1 to 10; for SAEs, Screening, Days 1 to 10 and up to 30 days post discontinuation of dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Infection, Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>Part 1 (BMS-663068+methadone)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Effect of multiple doses of BMS-663068, 600mg ER on the exposure of methadone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 (BMS-663068+buprenorphine and norbuprene)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Effect of multiple doses of BMS-663068, 600mg ER on the exposure of buprenorphine and norbuprenorphine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-663068</intervention_name>
    <description>BMS-663068</description>
    <arm_group_label>Part 1 (BMS-663068+methadone)</arm_group_label>
    <arm_group_label>Part 2 (BMS-663068+buprenorphine and norbuprene)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methadone</intervention_name>
    <description>Methadone</description>
    <arm_group_label>Part 1 (BMS-663068+methadone)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine and Norbuprenorphine</intervention_name>
    <description>Buprenorphine and Norbuprenorphine</description>
    <arm_group_label>Part 2 (BMS-663068+buprenorphine and norbuprene)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed Informed Consent

          2. Target population: Subjects on methadone maintenance therapy (for inclusion in Part 1)
             or buprenorphine and norbuprenorphine maintenance therapy (for inclusion in Part 2),
             who have been reliably participating in an oral methadone or buprenorphine and
             norbuprenorphine program and who are on a stable dose for at least 30 days prior to
             study screening

          3. Male and Female Subjects with body mass index of 18 to 34 kg/m2, inclusive

          4. Women of child bearing potential (WOCBP) with negative serum or urine pregnancy test
             and must not be breastfeeding

          5. Men and WOCBP must agree to follow instructions for contraception

        Exclusion Criteria:

          1. History of any chronic or acute illness, gastrointestinal disease, smoking and alcohol
             abuse

          2. Any Gastrointestinal (GI) surgery within 4 weeks of study drug administration that
             could affect its absorption

          3. Evidence of organ dysfunction or any clinically significant deviation from normal in
             physical examination, vital signs, ECG or clinical laboratory determinations beyond
             what is consistent with the target population.

          4. History of allergy to any drugs, BMS-663068, HIV attachment inhibitors, or related
             compounds
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>ViiV Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2016</study_first_submitted>
  <study_first_submitted_qc>January 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2016</study_first_posted>
  <last_update_submitted>August 8, 2017</last_update_submitted>
  <last_update_submitted_qc>August 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Methadone</mesh_term>
    <mesh_term>Buprenorphine, Naloxone Drug Combination</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

